# US 2009/0221697 A1 · Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221697 A1
- Document ID: US20090221697A1
- Status: Published application
- Kind: A1
- Application number: 11/996,801
- Filed: 2006-07-26
- Published: 2009-09-03
- Earliest claimed: 2005-07-26
- Assignees: Merckle GmbH
- Inventors: Stefan Laufer; Wolfgang Albrecht; Michael Burnet; Hans-Jürgen Gutke
- Web page: https://patentgrep.com/patent/US20090221697A1

## CPC

- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 273/00: Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and are therefore suitable to treat disorders of the rheumatic type and to prevent allergically induced diseases. The macrolide conjugates have significantly enhanced potency and efficacy.

## Claims

### Claim 1

A macrolide conjugate of formula I
wherein
R1 is hydroxy or C1-C4-alkoxy or
R1 and R4 together with the carbon atoms to which they are attached form a tetrahydrofurane ring,
R21 is
one of radicals R2 and R3 is OR9 and the other is NR6R7;
R4 is OH, OR9 or
R5 is H or
R4 and R5 together with the carbon atom to which they are attached form a carbonyl group;
R6 and R7 which may be the same or different are C1-C4-alkyl or R9O—C1-C4-alkyl;
R8 is H or R10;
R9 is H or R10;
R10 is
X is NR11CH2, CH2NR11, C═O or C═NOR20
R11 is H or C1-C4-alkyl;
R20 is H, R10 or —(CH2)k—Y—(CH2)I—Y—(CH2)m—CH3;
Y is O or a bond;
k is 1 or 2;
l is 1, 2 or 3;
m is 0, 1 or 2;
n is 0 or 1;
o is 1, 2, or 3;
p is 1, 2, or 3;
Z is
wherein
R12 and R13 which may be the same or different are selected from:
phenyl which is optionally substituted with 1 or 2 halogen, hydroxy, C1-C4-alkoxy, phenoxy, C1-C4-alkyl or CF3,
a 5- or 6-membered aromatic heterocyclic group containing 1, 2 or 3 heteroatoms selected from O, N, or S and which may be substituted with 1 or 2 halogen, C1-C4-alkyl or CF3,
a benzofused 5- or 6-membered aromatic heterocyclic group containing 1, 2 or 3 heteroatoms selected from O, N, or S and which may be substituted with 1 or 2 halogen, C1-C4-alkyl or CF3;
A is a bond or C1-C8-alkylene which can optionally be substituted by hydroxyl or
C1-C4-alkoxy;
B is CR14R15 or C═O;
R14 and R15 which may be the same or different are H or C1-C4-alkyl or one of radicals R14 and R15 is H, C1-C4-alkyl, hydroxy-C1-C4-alkyl or C1-C4-alkoxy-C1-C4-alkyl and the other is OH, C1-C4-alkoxy or C1-C4-alkylcarbonyloxy;
D is a bond between B and the carbon atom carrying R16 and R17 or is CH2;
R16 and R17 which may be the same or different are H, C1-C4-alkyl, hydroxy-C1-C4-alkyl or C1-C4-alkoxy-C1-C4-alkyl;
R18 and R19 which may be the same or different are H or C1-C4-alkyl or
two of radicals R16, R17, R18 and R19 form a double bond and the two others are H or C1-C4-alkyl,
and the pharmaceutically acceptable salts, solvates, hydrates and stereochemical isomers thereof.

### Claim 2 (depends on 1)

The macrolide conjugate according to claim 1, wherein R2 is OR9 and R3 is NR6R7.

### Claim 3 (depends on 2)

The macrolide conjugate according to claim 2, wherein R2 is OR10 and R3 is NR6R7, wherein R6 and R7 are C1-C4-alkyl.

### Claim 4 (depends on 2)

The macrolide conjugate according to claim 2, wherein R2 is OH and R3 is NR6R7, wherein R6 is C1-C4-alkyl and R7 is R10O—C1-C4-alkyl.

### Claim 5 (depends on 1)

The macrolide conjugate according to claim 1, wherein R2 is NR6 R7 and R3 is OR9.

### Claim 6 (depends on 5)

The macrolide conjugate according to claim 5, wherein R6 and R7 which may be the same or different are C1-C4-alkyl and R3 is OR10.

### Claim 7 (depends on 5)

The macrolide conjugate according to claim 5, wherein R6 is C1-C4-alkyl, R7 is R10O—C1-C4-alkyl and R3 is OH.

### Claim 8 (depends on 1)

The macrolide conjugate according to claim 1, wherein R4 is OH or

### Claim 9 (depends on 1)

The macrolide conjugate according to claim 1, wherein R4 and R5 together with the carbon atom to which they are attached form a carbonyl group.

### Claim 10 (depends on 1)

The macrolide conjugate according to claim 1, wherein
X is NR11CH2,
C═NO(CH2)kY(CH2)lY(CH2)m—CH3 or
C═NOR10,
wherein
R11 is C1-C4-alkyl and R10, Y, k, l and m are as defined in claim 1.

### Claim 11 (depends on 1)

The macrolide conjugate according to claim 1, wherein
R10 is Z or —CO—(CH2)o—Y—(CH2)p—O-Z, wherein Y is a bond and Z, o and p are as defined in claim 1.

### Claim 12 (depends on 1)

The macrolide conjugate according to claim 1 having formula Ia
wherein R4, R5, R21 and X are as defined in claim 1.

### Claim 13 (depends on 12)

The macrolide conjugate according to claim 12 selected from the formulae Iaa to Iaf:
wherein R6 and R7 which may be the same or different are C1-C4-alkyl;
wherein R6 is C1-C4-alkyl and R7 is hydroxy-C1-C4-alkyl or R10O—C1-C4-alkyl;
wherein R6 and R7 which may be the same or different are C1-C4-alkyl;
wherein R6 is C1-C4-alkyl and R7 is hydroxy-C1-C4-alkyl or R10O—C1-C4-alkyl;
wherein R6 and R7 which may be the same or different are C1-C4-alkyl;
wherein R6 is C1-C4-alkyl and R7 is hydroxy-C1-C4-alkyl or R10O—C1-C4-alkyl; and wherein in formulae Iaa to Iaf R4 is hydroxy or
and X, R8 and R10 are as defined above.

### Claim 14 (depends on 13)

The macrolide conjugate according to claim 13, wherein in formula Iaa to Iaf X is NR11CH2.

### Claim 15 (depends on 1)

The macrolide conjugate according to claim 1, wherein R12 and R13 which may be the same or different are phenyl, thienyl, furyl, pyrrolyl, imidazolyl, thiadiazolyl, oxazolyl, pyridinyl, pyrimidyl, benzofuryl, quinolyl, or indolyl and may be substituted with one or two halogens or CF3.

### Claim 16 (depends on 15)

The macrolide conjugate according to claim 15, wherein R12 and R13 which may be the same or different are phenyl, halogen-substituted phenyl, thienyl, halogen-substituted thienyl or benzofuryl.

### Claim 17 (depends on 15)

The macrolide conjugate according to claim 15, wherein R14, R15, R18 and R19 are H and R16 and R17 are H or C1-C4-alkyl.

### Claim 18 (depends on 1)

The macrolide conjugate according to claim 1, wherein Z is
wherein A is a bond or C1-C8-alkylene,
R12 is phenyl, halogen-substituted phenyl, thienyl, halogen-substituted thienyl, or benzofuryl;
R13 is phenyl;
R16 and R17 are H or C1-C4-alkyl; and
R18 and R19 are H.

### Claim 19 (depends on 18)

The macrolide conjugate according to claim 18, wherein A is CH2 and R12 is chlorophenyl, chlorothienyl or benzofuryl.

### Claim 20 (depends on 19)

The macrolide conjugate according to claim 19, wherein R12 is 4-chlorophenyl, 5-chlorothien-2-yl or benzofur-2-yl.

### Claim 21 (depends on 20)

The macrolide conjugate according to claim 20, wherein Z is

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a macrolide conjugate as defined in claim 1, together with a pharmaceutically acceptable excipient.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22 in the form of a parenteral or topical formulation.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of treating rheumatic type disorders, which comprises administering to an individual in need of such treatment an effective amount of a macrolide conjugate according to claim 1.
